AI-generated research brief — verify at source
PROGRESS Trial Launches First Large RCT of Early TAVR in Moderate Aortic Stenosis
The PROGRESS trial is a prospective, randomized, controlled study enrolling up to 750 patients to compare early transcatheter aortic valve replacement against clinical surveillance in moderate aortic stenosis; no outcome results are yet available as this publication describes only the trial design and rationale. The trial addresses a critical evidence gap, given that observational data have consistently linked moderate aortic stenosis to elevated morbidity and mortality, yet no large randomized trial has previously evaluated whether earlier intervention alters that trajectory.
What Was Studied
The trial investigates whether early intervention with transfemoral transcatheter aortic valve replacement (TAVR) using the SAPIEN 3 platform (Edwards Lifesciences) improves outcomes compared to standard clinical surveillance in patients with moderate aortic stenosis who have at-risk features. The primary effectiveness endpoint is the composite of death or heart failure event, with or without hospitalization, assessed at two years — a clinically meaningful benchmark chosen to capture both mortality and functional deterioration in this population.
How It Was Studied
PROGRESS is a prospective, open-label, randomized, multicenter, controlled trial with a 1:1 allocation between transfemoral TAVR and clinical surveillance. The study targets enrollment of up to 750 patients with moderate aortic stenosis and at-risk features, stratified by enrolling site, left ventricular ejection fraction, and peak jet velocity to ensure balanced distribution of key prognostic variables. A primary safety endpoint — evaluated exclusively in the TAVR arm — is assessed at 30 days and captures a composite of death, stroke, life-threatening or fatal bleeding, acute kidney injury stage 4, procedure- or device-related hospitalization, and valve dysfunction requiring reintervention. Beyond the two-year primary endpoint, patients will undergo annual follow-up extending through 10 years, allowing assessment of long-term valve durability and clinical outcomes.
What Was Observed
- This is a design and rationale publication; no efficacy or safety outcome data have yet been reported. The trial is ongoing, and results for the primary effectiveness endpoint at two years are not yet available.
- The study is powered around a composite primary endpoint of death or heart failure event at two years, reflecting the expectation — based on observational evidence — that moderate aortic stenosis with at-risk features carries meaningful near-term clinical risk even before progression to severe disease.
- The 30-day primary safety endpoint, restricted to the TAVR arm, incorporates six component events including stroke, major bleeding, acute kidney injury stage 4, and valve dysfunction requiring reintervention, providing a structured framework for procedural risk evaluation in this lower-severity population.
- Annual follow-up through 10 years is planned, enabling investigation of questions about structural valve deterioration and late clinical outcomes that two-year data alone cannot resolve.
Why This Matters
Current U.S. guidelines recommend clinical surveillance every one to two years for patients with moderate aortic stenosis, a strategy that has not been rigorously tested against earlier intervention in a randomized setting. Multiple observational studies have associated moderate aortic stenosis with increased morbidity and mortality, raising the hypothesis that earlier TAVR might improve outcomes before the valve deteriorates further. PROGRESS is the first large randomized trial designed to directly test this hypothesis, and its results could have meaningful implications for how moderate aortic stenosis is managed across cardiology practice.
How to Read This Result
Because this publication reports only the trial design and enrollment rationale, no conclusions about the clinical benefit or risk of early TAVR in moderate aortic stenosis can yet be drawn; the evidence base for or against early intervention in this population remains open and awaits the trial’s primary outcome data.
Limitations
The abstract does not explicitly report study limitations.